Generated by AI
Agios Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing medicines for rare diseases through its expertise in cellular metabolism. The company’s core commercial product is PYRUKYND (mitapivat), an oral pyruvate kinase activator used in hemolytic anemia associated with pyruvate kinase deficiency, with additional development in other hematologic and genetically defined disorders. Agios is also advancing investigational therapies for conditions such as thalassemia, sickle cell disease, and phenylketonuria, reflecting its emphasis on rare disease biology and precision medicine. The company operates as a specialized hematology and rare disease developer, combining drug discovery, clinical development, and commercialization capabilities to address unmet medical needs. Agios Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts.
Website88 Sidney Street
Cambridge, MA, 02139
United States
The latest articles about AGIO.
Agios Pharmaceuticals Inc (AGIO) posted record Q3 2026 revenue of $55.4 million, cut R&D headcount by over 35%, and is launch-ready for sickle cell ahead of a February 2027 PDUFA date.
Summary of Oct 30's posts. Generated by AI.
Summary of Dec 24's posts. Generated by AI.
Summary of Jun 15's posts. Generated by AI.
Summary of Dec 24's posts. Generated by AI.
Investors talking about AGIO also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.